emjreviews.com1d
No Survival Benefit for Chemoradiotherapy in Oesophageal Cancer
Read on to learn how the impact of chemoradiotherapy for patients receiving neoadjuvant chemoradiotherapy followed by surgery ...
Business Wire2d
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroes…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...